<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454855</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-K13-170</org_study_id>
    <secondary_id>2014-003505-14</secondary_id>
    <nct_id>NCT02454855</nct_id>
  </id_info>
  <brief_title>Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients</brief_title>
  <acronym>MEQAPAG</acronym>
  <official_title>Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients (&gt; = 70 Years) - PHRC-K13-170</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melatonin may represent an effective complementary treatment to standard chemotherapy in
      order to reduce asthenia, depression, sleep disturbances, cognitive impairment and
      performance status as part of quality of life. Moreover, melatonin has been evaluated in
      several clinical trials in cancer patients with no side effects . It could be particularly of
      interest in elderly cancer patients as they exhibit a significant deficiency of melatonin
      production .

      The investigators propose to perform a prospective and randomized study to study the effect
      of a melatonin supplementation on the quality of life of elderly advanced/metastatic cancer
      patients (age ≥ 70) treated by chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of average individual variation of overall score of QLQ-C30 of the 2 groups &quot;Melatonin&quot; and control (placebo)</measure>
    <time_frame>3 months</time_frame>
    <description>The quality of life will be assessed using the QLQ-C30 questionnaire. the change in absolute value (inclusion versus after 3 months of supplementation) of overall score of QLQ-C30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sub-scores of QLQ-C30 questionnaire especially dimensions &quot;symptoms&quot; and &quot;functional&quot;</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>longitudinal evolution of QLQ-C30 scores</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of scores of QLQ-ELD14</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep quality: Questionnaire Leeds</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue: visual analog scale (VAS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain: VAS</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression: Questionnaire GDS (Geriatric Depression Scale)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance: assessed and graded according to the NCI-CTC (National Cancer Institute Common Toxicity Criteria) version 4.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>one year Overall survival rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>one year recurrence-free survival rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function: MMS (mini-mental score) or Folstein test</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of autonomy: ADL-IADL questionnaires</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment</measure>
    <time_frame>3 months</time_frame>
    <description>counting of remaining tablets during the 3 months of supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of the appetite with an EVA</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of the effect of melatonin on anorexia will be achieved through the evaluation of the appetite with an EVA 10 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of Dietary intake with dietary questionnaires</measure>
    <time_frame>1 year</time_frame>
    <description>Dietary intake may be assessed using dietary questionnaires taken on the last 3 days, only for patients at risk of malnutrition or poor nutritional status, detected during the geriatric assessment (according to the MNA questionnaire assessing status nutritional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretion of melatonin: urinary concentration of 6-sulfatoxy-melatonin (urine night 12h), with normalization on creatinuria</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circadian rhythms of activity / rest: survey using actimeters worn for 48 hours</measure>
    <time_frame>baseline and after 3 months of treatment</time_frame>
    <description>Evaluation for only 80 patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Group &quot;Melatonin&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard chemotherapy + 3-month of melatonin supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;Placebo&quot;</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard chemotherapy + placebo (3 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line chemotherapy.
Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg.</description>
    <arm_group_label>Group &quot;Melatonin&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line chemotherapy.</description>
    <arm_group_label>Group &quot;Placebo&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; = 70 years.

          -  Performance status &lt; = 2 (WHO criteria)

          -  Life expectancy &gt; 3months

          -  A patient with solid tumor locally advanced or metastatic

          -  Indication of chemotherapy treatment with oral or IV chemotherapy

          -  Patient starting chemotherapy line, in 1, 2 or 3rd line

          -  MMS-orientation ≥ 7 (geriatric Mini Mental State face-to-face questionnaire)

          -  Able to swallow and retain oral treatment

          -  Patient who signed the participation consent before entering the trial

          -  Patient able to read, write and understand French.

          -  Affiliation to the french social security scheme (or beneficiary of such a scheme)
             under the terms of the law of 9 August 2004.

        Exclusion Criteria:

          -  Over 3 chemotherapy treatment lines

          -  Haematological cancers

          -  Indication of treatment by hormonotherapy or targeted therapy only

          -  Renal failure or hepatic failure

          -  Auto-immune disease

          -  Diagnosed neurodegenerative diseases

          -  Unability to fill out questionnaires

          -  melatonin treatment ongoing or completed for less than 3 months

          -  Treatment with an investigational drug, participation to another therapeutic clinical
             trial within &lt;30 days

          -  Hypersensitivity to melatonin or any of the excipients

          -  Current Treatment with fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, estrogen

          -  A history of known or suspected excessive alcohol use.

          -  Patient refusing to participate and / or unable to give informed consent

          -  Patient unable to complete the questionnaires even with the help of a relative or a
             nurse

          -  Patient does not have the capacity to comply with the study requirements

          -  Patient deprived of liberty by a court or administrative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier DURANDO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier DURANDO, MD</last_name>
    <phone>33 473278089</phone>
    <email>Xavier.DURANDO@cjp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'ouest - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie ABADIE-LACOURTOISIE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre KALISKI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier DURANDO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier DURANDO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon-Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique MARI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'ouest - Site René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle BOURBOULOUX, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul-Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pasquale INNOMINATO, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>melatonin</keyword>
  <keyword>Elderly patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

